Telmisartan blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of Angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle7 and the adrenal gland.

Telmisartan is used to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial  infarctions. It’s also used to reduce risk in patients unable to take ACE inhibitors.

For hypertension the dose is 40 mg once daily and maximum dose is 80 mg once daily. Blood pressure response is dose related over the range of 20 mg to 80 mg. For Cardiovascular (CV) risk reduction dose is 80 mg once daily.

Upper respiratory tract infection, Back pain, Sinusitis, Diarrhea, Pharyngitis, influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, fatigue, coughing, nausea, peripheral edema, increased sweating, flushing, allergy, fever, leg pain, malaise, palpitation, angina pectoris, tachycardia, abnormal ECG, insomnia, migraine, vertigo, paresthesia, hypoesthesia, flatulence.

Hypotension: In some patients symptomatic hypotension may occur after initiation of therapy with Telmisartan. Hyperkalemia: Hyperkalemia may also occur in some patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. Impaired Hepatic Function: Patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance. Initiate Telmisartan at low doses and titrate slowly in these patients.

Patients who are hypersensitive to any component of this product, Aliskiren, ACE inhibitors.

Digoxin: When co-administered with digoxin, median increases & digoxin peak plasma concentration was observed. Non-Steroidal Anti-Inflammatory agents including selective COX-2 inhibitors: In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including Telmisartan, may result in deterioration of renal function including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Telmisartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including Telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.

Pregnancy: USFDA pregnancy category C (first trimester) and D (second and third trimester). Telmisartan can cause fetal harm when administered to a pregnant woman. Lactation: There is no information regarding the presence of Telmisartan in human milk. Nursing woman should not breastfeed during treatment with Telmisartan.

Store at temperature not exceeding 30 o C in a dry place. Protect from light & moisture.